Discovery to Diagnostics Whitepaper Part 2
Neurological disorders impact an estimated one billion individuals globally, causing significant long-term disabilities and claiming an estimated nine million lives each year(1). Despite notable advancements in promising new therapeutics, early and accurate diagnosis remains paramount to optimizing treatment response and slowing neurodegeneration and disease progression.
Recent strides in neurological research have highlighted the critical role of biomarkers. Biomarkers serve as indicators of normal biological processes, pathogenic processes, or biological responses to an exposure or intervention(2) and are emerging as pivotal tools in clinical research and healthcare. Numerous studies have underscored their potential in drug development, diagnosis, prognosis, monitoring, and precision medicine. However, thorough validation is paramount for the adoption of these biomarkers in clinical settings. Download our whitepaper to learn more.
1. Feigin VL, Vos T, Nichols E, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neural. 2020;19(3):255-265. doi:10.1016/S1474-4422(19)30411-9
2. FDA-NIH Biomarker Working Group. BEST (Biomarkers, Endpoints, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016-. Glossary. 2076 Jan 28 [Updated 2021 Nov 29]. Available from: ncbi.nlm.nih.gov/books/NBK338448/
Related Posts
Mapping the Tau Cascade: New Insights from p-Tau 205 and p-Tau 212 for Disease Staging and Monitoring
NPTX2: A Synaptic Biomarker of Circuit Integrity, Cognitive Resilience, and Neurodegeneration
Neurology
Advancing Translational Neuroscience with the Simoa Mammalian GFAP Assay
Publication Brief Understanding astrocyte biology is essential for advancing translational neuroscience. GFAP has emerged as a leading biomarker of CNS injury, and Simoa® technology now enables its ultra-sensitive detection directly…
Proteomics in Transition: From Discovery to Diagnostic Relevance
Proteomics is moving beyond broad discovery to deliver real-time, clinically meaningful insights. At the forefront is Quanterix’s Simoa® digital immunoassay technology, enabling ultra-sensitive, reproducible detection of low-abundance biomarkers in areas…
Neurology
Beyond Blood: Expanding Simoa Applications in Urine, Saliva, Sweat, and Tears
Publication Brief The Quanterix Simoa® platform, known for ultrasensitive detection in plasma, serum, and CSF, now delivers the same performance in alternative matrices—urine, saliva, sweat, and tears. This publication brief…
Immunology
Simoa® IL-17A Advantage PLUS: Potential Biomarker Applications in Health and Disease
App Note IL-17A is a potent pro-inflammatory cytokine that plays critical roles in inflammatory responses, host defense against infections, and tissue regeneration. This application note delves into the physiological and…
Neurology
Beyond Blood: Tear Fluid as a Window into Biomarker Discovery
While blood and CSF have long dominated biomarker research, tear fluid is emerging as a scientifically relevant, non-invasive matrix for detecting systemic and neurological biomarkers. Produced by lacrimal glands and…
Neurology
Sweat As A Non-Invasive Matrix for Cytokine Detection Using Simoa®
Inflammatory cytokines like IL-6, IL-10, and TNF-α are central to understanding aging, immune dysregulation, and chronic disease. With eccrine glands distributed across the body, sweat offers a non-invasive, physiologically relevant…